CovidVax show full list


CureVac + Bayer
vaccine type: RNA-based
Distribution updates
Jan 17Bayer is examining whether it can help CureVac to produce its experimental COVID-19 vaccine (by
Aug 16CureVac expects to be on the market by mid 2021 (by
Human Testing updates (clinical trials)



started June 18 2020

with 284 healthy volunteers aged 18-60

trial location: Germany

» clinical trial details

PHASE 2 (South America)


started September 28 2020

with 660 healthy volunteers aged 18+

trial location: Panama and Peru

» clinical trial details

PHASE 2-3 (Tuebingen, Ger)


started December 14 2020

with 36500 healthy volunteers aged 18+

trial location: Tuebingen, Germany

» clinical trial details

PHASE 3 (Mainz, Ger)


started December 18 2020

with 2520 healthy volunteers aged 18+

trial location: Mains, Germany

» clinical trial details

Dec 22CureVac has announced the initiation of Phase 3 clinical study of its vaccine in healthcare workers in Germany (by
Dec 21CureVac announced that the first participant in a Phase 3 study of its vaccine will be vaccinated on Dec.22 (by
Dec 14CureVac announced today that it has enrolled the first participant in the Phase 2b/3 trial by including 35000+ participants in Europe and Latin America (by
Nov 02CureVac announced positive interim data from its ongoing Phase 1 of its vaccine candidate (by
Sep 29CureVac announced today that the first participant has been dosed in a Phase 2 clinical trial of its vaccine (by
Sep 29CureVac plans to begin a global late-stage trial with about 30000 volunteers in Q4 2020 (by
Jul 28None of the 50 Belgian participants in a study on CureVac's vaccine showed any serious side effects (by
Jun 17CureVac received regulatory approval from German and Belgian authorities to start phase 1 trial (by
Apr 03German labs have told regulators to lower clinical trial bar if they want vaccine quickly (by
Animal Testing updates (pre-clinical trials)
start date: April 2020
Jan 11CureVac's COVID-19 vaccine showed efficient protection of non-human primates during coronavirus infection (by
Oct 23CureVac announced data from preclinical studies of its vaccine candidate in mice and hamsters (by
May 14CureVac's vaccine candidate showed positive results at a low dose against SARS-CoV-2 (by
Mar 19CureVac expects to have a vaccine candidate ready for animal testing by April 2020 (by
early development updates
currently no early development info

Coalition for Epidemic Preparedness (CEPI) + European Commission + 300 million Euros by Federal Republic of Germany
Sep 04CureVac is expected to receive up to 252 million Euros from BMBF to further develop its vaccine (by
Jun 15German government will invest 300M Euros on CureVac's further development of the company (by
Jun 07CureVac's vaccine will be supported by EIB with a €75 million loan agreement on its development (by
Mar 17CureVac has been granted up to €80M by the EU to scale up vaccine's production (by
Jan 07Bayer has signed a collaboration with Curevac aiming at supporting the further development,supply and key territory operations of CureVAc's vaccine (by

contact | about | ©2020 project